May 26, 2021 8:04am

Although, I believe that the sector will feel the effects of being oversold and recognized by the return of some value!

Pre-open indications: 1 BUY – PSTI; 1 Maintain SELL - BSTG 

My version of the morning’s “indications” is written on what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.19% (+65 points), S&P futures are UP +0.29% (+12 points) and NASDAQ futures are UP +0.44% (+59 points)

 

U.S. stock futures are advancing in the pre-market trade on Wednesday,

European stocks were mostly higher,

Asia-Pacific stocks were also mostly higher with multiple markets in Southeast Asia (in Indonesia, Singapore and Thailand) closed for a holiday.

 

Data Docket: Investors are awaiting a speech from Federal Reserve Vice Chair Randal Quarles as some concerns surrounding inflation and potential tapering continue to linger.

 

Henry’omics:

Monday and Tuesday were lost leaders for the cell and gene therapy sector, today should offer an awakening of oversold value – hopefully.

Like I stated, last night, take a “little blue pill that will help confidence”! It’s wait for the after-effect for it does take time to load

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (31) to date …  https://www.regmedinvestors.com/articles/11628

 

Tuesday’s evening’s recap: “sector needs a blue pill to increase its confidence. It's a need you get when everyone sold into negative sentiment that seems like a delusion yet, a set-up for the oversold to “pose” for gain.” … https://www.regmedinvestors.com/articles/11927

  • The Nasdaq closed DOWN -4 points (-0.03%);
  • The IBB closed down -0.51% and XBI closed down -1.26%;
  • Sector volume was LOW with 0 of the 10-upside having higher than the 3-month average volume with the volume of 5 of 23-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.44 points or +2.39% at 18.84
  • Tuesday’s percentage (%) of the 10-upside were +0.23% (VCEL) to +3.07% (NTLA) while the 23-downside ranges from -0.19% (CLLS) to -4.21% (PSTI);

Q2/21

May:  6 positive and 11 negative closes

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell and still “pumping” the volume to keep price moving …

Biostage (BSTG) closed flat at $1.30 again with 358 shares traded after Monday’s flat with 45 shares traded, Friday’s +$0.02 to $1.32 with 299 shares traded, Thursday at $1.30 with 1 share traded and last Wednesday’s +$0.16 to $1.30 with 930 shares traded.

Question#1: After earnings’ release, WHAT is there to invest in, an IND a year old with NO clinical trial, NO management, barely any employees and huge overhead (buildings etc.) expense with WHAT capacity to finance? With only $500 K in the “till” and a two (2) month runway with a $900 K “spend”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

Question#2: Where is William (BILL) Fodor PhD, the chief scientific officer of BSTG, who was RESPONSIBLE for the IND and the NON - clinical trial initiation, what’s the 1 year plus hold-up? WHY the silence? Did you rush the initial filing to the FDA with-out considering all the ramifications (?); were not 4 adult patients to be tested, implemented and measured before the pediatric IND could be EVEN considered by a secondary filing of results from the first studies?

  • You are RESPONSIBLE, WHY the let-down to shareholders? Definitely NOT a resume builder event of your first IND?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications: I am “sitting-out” this a.m. re forecasting indications – there is still an anxiety snaking through the sector.

Although, I believe that the sector will feel the effects of being oversold and recognized by the return of some value!

Consider a broad-brush approach – one in particular!

Pluristem (PSTI +$0.03 or +0.82% after a nasty fall of -$0.16 to $3.64 on news of yesterday’s $25 million non-dilutive funding

 

The BOTTOM LINE: I feel like a song from a broken record, “post earnings’ release, BUY some (few) short-term dips but, cautiously”.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.